Clinical Trial

An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on Cognition

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This open label study aims to evaluate whether the consumption of probiotics can improve symptoms and overall quality of life in individuals experiencing cognitive decline symptoms, as well as to evaluate the effects of probiotics on blood-related biomarkers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-04; most recent amendment 2025-11-27.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-11-27
Trial Details
NCT Number NCT07168824
Lead Sponsor Chi-Chang Huang
Collaborators: Bened Biomedical Co., Ltd.
Conditions Subjective Cognitive Decline (SCD)
Enrollment 40 participants
Start Date 2025-10-17
Primary Completion 2026-08-18 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-05